Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Health Network, Toronto
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Age ≥18yrs
ECOG performance status ≤2
Histologically or cytologically confirmed adenocarcinoma of the prostate
Clinical or radiological evidence of metastatic disease
Disease progression while receiving androgen deprivation therapy with an increase in PSA of 25% or greater over nadir value measured on 3 consecutive occasions at least 1 week apart
Antiandrogen therapy must have been stopped at least 4 weeks prior to start of trial treatment (6 weeks in the case of bicalutamide or nilutamide)if there was a reduction in serum PSA after this therapy was initiated
Adequate hepatic and renal function: total bilirubin level ≤1.5 x ULN (unless secondary to documented Gilbert's disease); ALT,AST, and creatinine ≤1.5 x ULN
Ability to understand and to sign consent for the study
You may not be if
Prior treatment for prostate cancer with chemotherapy or radioisotopes
History of another cancer within the preceding five years (except basal or squamous-cell skin cancer or adequately treated superficial bladder cancer)
Known or suspected brain or leptomeningeal metastases
Symptomatic peripheral neuropathy of grade 2 or higher
Major surgery within 4 weeks of start of trial treatment
Radiotherapy to ≥25% of the bone marrow and any radiotherapy within 4 weeks of start of trial treatment
Known hypersensitivity to trial treatment or hypersensitivity to any of its components
Any concomitant drugs contraindicated for use with the trial treatment
Any serious underlying medical condition which could impair the ability of the patient to participate in the trial
Any psychological, familial, sociological or other patient related factors that might preclude compliance with the study protocol
Clareo Health | Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer
